» Articles » PMID: 25967542

Validation of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): A Cognitive Tool for Motor Disorders

Overview
Specialty Neurology
Date 2015 May 14
PMID 25967542
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Our objective was to assess the validity of the Edinburgh Cognitive and Behaviour ALS Screen (ECAS), a multi-domain screen designed to detect cognitive deficits in patients with motor disorders. Forty ALS patients (without pre-diagnosed dementia) and 40, age-, gender- and education-matched healthy controls were recruited. All participants underwent extensive neuropsychological assessment and the ECAS. Performance at neuropsychological assessment across five domains (fluency, executive function, language, memory and visuospatial function) was compared to the ECAS ALS-Specific (fluency, executive functions and social cognition, language), ALS Non-specific (memory, visuospatial functions), and Total scores. Data from the healthy controls produced population-based abnormality cut-offs: composite score performance ≤ 2 SD in any domain classified impairment at neuropsychological assessment. Thirty-three percent of patients were impaired, most commonly in a single domain (executive or language dysfunction). Receiver Operator Curve (ROC) analyses using ECAS Total scores and ALS-Specific scores revealed 85% sensitivity and 85% specificity in the detection of cognitive impairment characteristic of ALS (fluency, executive function, language). A five-point borderline range produced optimal values (ALS-Specific Score 77-82, and ECAS-Total Score 105-110). In conclusion, validation against gold standard extensive neuropsychology demonstrated that the ECAS is a screening tool with high sensitivity and specificity to impairment characteristic of ALS.

Citing Articles

Screening of visuospatial abilities in amyotrophic lateral sclerosis (ALS): a pilot study using the battery for visuospatial abilities (BVA).

Sharbafshaaer M, Siciliano M, Passaniti C, SantElia V, Silvestro M, Russo A Orphanet J Rare Dis. 2025; 20(1):110.

PMID: 40057753 PMC: 11890512. DOI: 10.1186/s13023-025-03645-z.


Neuroimaging correlates of domain-specific cognitive deficits in amyotrophic lateral sclerosis.

Tan H, Nitert A, van Veenhuijzen K, Dukic S, van Zandvoort M, Hendrikse J Neuroimage Clin. 2025; 45:103749.

PMID: 39947099 PMC: 11869911. DOI: 10.1016/j.nicl.2025.103749.


The Basis of Cognitive and Behavioral Dysfunction in Amyotrophic Lateral Sclerosis.

Bampton A, McHutchison C, Talbot K, Benatar M, Thompson A, Turner M Brain Behav. 2024; 14(11):e70115.

PMID: 39501538 PMC: 11538089. DOI: 10.1002/brb3.70115.


Cognitive reserve in individuals with frontotemporal dementia: a systematic review.

Grebe L, Vonk J, Galletta E, Goral M J Clin Exp Neuropsychol. 2024; 46(8):718-741.

PMID: 39420515 PMC: 11617274. DOI: 10.1080/13803395.2024.2410207.


From suspicion to diagnosis: exploration strategy for suspected amyotrophic lateral sclerosis.

Garnier M, Camdessanche J, Cassereau J, Codron P Ann Med. 2024; 56(1):2398199.

PMID: 39233624 PMC: 11378651. DOI: 10.1080/07853890.2024.2398199.